Read by QxMD icon Read

sulodexide for dvt

Gianni Belcaro, Mark Dugall, Shu Hu, Beatrice Feragalli, Roberto Cotellese, Andrea Ledda, Marcello Corsi, Andrea Ricci, Edmondo Ippolito, Bruno M Errichi, Umberto Cornelli, M Rosaria Cesarone, Morio Hosoi
BACKGROUND: This retrospective registry study evaluated different managements on the development of post-thrombotic syndrome (PTS) and recurrent deep venous thrombosis (R-DVT). The effects of aspirin (100 mg/day), added to the "standard management" (SM) (IUA consensus), were observed in patients after a proximal DVT. METHODS: The study started after the anticoagulant period. Comparable groups used the mild-antithrombotic agent Pycnogenol® (200 mg/day), ticlopidine (250 mg/day) or sulodexide (500 ULS/day)...
June 2018: Minerva Cardioangiologica
Giuseppe M Andreozzi, Angelo A Bignamini, Giovanni Davì, Gualtiero Palareti, Jiří Matuška, Martin Holý, Katarzyna Pawlaczyk-Gabriel, Andrej Džupina, German Y Sokurenko, Yury P Didenko, Laurentia D Andrei, Gianfranco Lessiani, Adriana Visonà
BACKGROUND: Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known. METHODS AND RESULTS: In this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings...
November 17, 2015: Circulation
Roberta Luzzi, Gianni Belcaro, Mark Dugall, Shu Hu, Guido Arpaia, Andrea Ledda, Edmondo Ippolito, Marcello Corsi, Andrea Ricci, Roberto Cotellese, Giovanni Agus, Bruno M Errichi, Umberto Cornelli, M Rosaria Cesarone, Morio Hosoi
AIM: The aim of this open, observational registry was to evaluate the effects of antithrombotic treatment on the development of postthrombotic syndrome (PTS): the effects of "standard management" (SM; according to International Union of Angiology guidelines) were compared to SM in association with sulodexide or aspirin. METHODS: Postthrombotic syndrome occurrence was observed in 3 nonparallel groups after deep venous thrombosis (DVT); the registry started after the end of the anticoagulation period...
September 2014: Clinical and Applied Thrombosis/hemostasis
J Lasierra Cirujeda, P Coronel Granado
This study was carried out to study the safety and efficacy of a fixed dosage of sulodexide compared to adjusted dosages (INR) of acenocoumarol as secondary prophylaxis in patients with deep vein thrombosis (DVT) in lower limbs. An economic evaluation based on the criteria of use in normal clinical practice was also performed. One hundred and fifty patients of both sexes were included, all over 18 years of age and diagnosed with proximal DVT of the lower limbs by color echo-Doppler, and with clinical evolution of less than 1 month...
January 2006: Angiology
B M Errichi, M R Cesarone, G Belcaro, R Marinucci, A Ricci, A Ippolito, R Brandolini, G Vinciguerra, M Dugall, A Felicita, L Pellegrini, G Gizzi, M Ruffini, G Acerbi, P Bavera, A Di Renzo, M Corsi, M Scoccianti, M Hosoi, M Lania
The aim of this study was to evaluate the prevention of recurrent deep vein thrombosis (R-DVT) with an oral antithrombotic agent (sulodexide) in moderate to high-risk subjects. A group of 405 patients was included into the multicenter registry. Both compression and an exercise program were used as well as a risk-factors control plan. After diagnosis of DVT, patients were treated with oral anticoagulants for 6 months. At the end of this period a coagulation study was made and patients started treatment with oral sulodexide capsules for a period of 24 months...
May 2004: Angiology
A Pinto, S Corrao, D Galati, S Arnone, A Licata, G Parrinello, T Maniscalchi, G Licata
Thirty adult patients with distal, monolateral deep vein thrombosis of the lower limbs were randomly treated for sixty days either with subcutaneous Ca-Heparin or with Sulodexide, administered IM for ten days and orally for fifty days. The thrombus accretion above the knee, the venous pressures of the affected leg, the clinical symptomatology, and some laboratory coagulative tests were monitored throughout the administration period. Local tolerability of the two treatments was also evaluated. The two applied treatments evidenced a net antithrombotic activity, preventing thrombus accretion above the knee, improving with the same efficacy the venous pressures in the affected legs, and similarly reducing clinical symptoms, with a quick and statistically significant trend toward normalization...
September 1997: Angiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"